Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
John Waas
University of Pittsburgh - Medical Center (UPMC)
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
87
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
A Phase II Clinical Trial Evaluating the Safety and Efficacy of Durvalumab as First Line Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer Patients with Eastern Cooperative Oncology Group Performance Status of 2
Number of pages: 24
Posted: 07 Aug 2023
Khvaramze Shaverdashvili
,
Vincent Reyes
,
Hong Wang
,
Dhaval Mehta
,
Christopher Marsh
, John Waas,
Robert VanderWeele
,
Sajid Peracha
,
Hongmei Liang
,
Mark Socinski
,
David Gerber
,
Jonathan Dowell
and
Lisa C. Villaruz
University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Texas at Dallas - Southwestern Medical Center, University of Texas at Dallas - Southwestern Medical Center and University of Pittsburgh - Medical Center (UPMC)
Downloads
87
(765,566)
View PDF
Download
Abstract:
Durvalumab, non-small cell lung cancer, safety, overall survival, performance status 2
Feedback